Ibutilide Administration During Pulmonary Vein Ablation
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
To test the hypothesis that localized functional reentry maintains Afib in humans, ibutilide
will be administered intravenously in patients undergoing an Afib ablation. The hypothesis of
this study is that ibutilide will decrease the high frequency signals observed in Afib
suggesting the presence of micro reentrant circuits as the basic mechanism of Afib,
especially for the paroxysmal Afib group. The potential difference in response to the
ibutilide in patients with paroxysmal versus persistent Afib may show the difference in the
underlying mechanism of Afib between these two groups.